Bristol-Myers Squibb Articles
IQWiG re-assessments come up with same view for saxagliptin and different for crizotinib
14 May 2013
Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx
6 May 2013
Highlights of presentations from Bristol-Myers, J&J, Gilead and AbbVie at EASL meeting
24 April 2013
Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon
23 April 2013
Santaris Pharma in multi-million dollar deal with Bristol-Myers for RNA-targeted medicines
17 April 2013
Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head
8 April 2013
Advantages of Tivopath over currently used kidney cancer therapies seen by thought leaders
27 March 2013
Higher risk of pancreatitis for those taking new class of diabetes drugs, Johns Hopkins study finds
26 February 2013
Bristol-Myers gets $438 million under Latin America OTC deal with Reckitt Benckiser; Baraclude patent ruled invalid
13 February 2013
Bristol-Myers beats expectations, as new products kick in
25 January 2013
News briefs: Novartis drops Ruvise MAA; B-MS settlement; Germany donates to Global Fund
25 January 2013
Negative NICE final guidance for Pierre Fabre's Javlor in bladder cancer; fast-track FAD for Eliquis
23 January 2013
US FDA finally approves Bristol-Myers/Pfizer's Eliquis for stroke prevention in AF patients
31 December 2013
Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis
27 December 2012
Brazil's atrial fibrillation market to grow at 31% annually over the next five years
19 December 2012
The Medicines Company in over $105 million deal with Bristol-Myers for Recothrom; buys Incline Thera
14 December 2012
UK's NICE draft guidance recommends Bristol-Myers Orencia for RA
6 December 2012
Another Alzheimer's drug hits the dust as Bristol-Myers drops avagacestat development
4 December 2012
Prognosis for renal cell carcinoma market development
27 November 2012
Use of low-molecular-weight heparins and vitamin K antagonists for VTE set for sharp decline as oral agents roll out
21 November 2012
Atrial fibrillation drug market will grow from $2.7 billion in 2011 to $9.2 billion in 2021
13 November 2012
EU approves label change for Bristol-Myer's Baraclude
6 November 2012
Bristol-Myers and Pfizer collaborate on Eliquis study with Portola's universal Factor Xa inhibitor antidote PRT4445
5 November 2012
Bristol-Myers goes into red, on charges and Plavix sales slump
25 October 2012
Sanofi buys Colombian drugmaker; Presents encouraging eliglustat and Lyxumia data; Revizes deal with B-MS
3 October 2012
Top executive appointments at Boehringer and Bristol-Myers
1 October 2012
FDA sets March 2013 PDUFA date for re-submitted Eliquis
28 September 2012
New uses of Cialis, Votubia, Galvus, Eucreas and Eliquis backed by CHMP, but not Qsiva
24 September 2012
Bristol-Myers links with Vanderbilt for Parkinson's research
23 September 2012
Top drugmakers set up non-profit TransCelerate to speed pharma R&D
20 September 2012
Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report
18 September 2012
Decline in cardiovascular drugs noted at ESC congress
17 September 2012
Summit licenses Seglin technology to Bristol-Myers
12 September 2012
Teva launches generic Aprovel in UK
30 August 2012
US genericization of clopidogrel will initially contract ACS market, before uptake of novel oral agents lifts sector to $2.7 billion
27 August 2012
Bristol-Myers drops hep C pill on patient safety issues
24 August 2012
Yervoy and Zelboraf rapidly penetrating metastatic patient population in USA and Europe
23 August 2012
AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance
10 August 2012
News briefs: setbacks for B-MS hep C drug; Baxter's HyQ
2 August 2012
Amylin seduced by $5.3 billion bid from Bristol-Myers; AstraZeneca chips in for share of the action
2 July 2012
More news at EULAR from Novartis, J&S and B-MS
7 June 2012
Germany's G-BA backs Eisai's Halaven; IQWiG finds some added benefit for Eliquis and rilpivirine
23 April 2012
German IQWiG finds mixed added benefits for Eliquis
2 April 2012
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
